A novel anti-parkinsonian agent, zonisamide, attenuates MPTP-induced neurotoxicity in mice

Journal of Molecular Neuroscience

Volumn 39, Issue 1-2, 2009, Pages 211-219

  Yano, Ryohei ^a   Yokoyama, Hironori ^a   Kuroiwa, Hayato ^a   Kato, Hiroyuki ^b   Araki, Tsutomu ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

Author keywords

Dopaminergic system; Immunohistochemistry; MPTP; Parkinson's disease; Western blot analysis; Zonisamide

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3,4 DIHYDROXYPHENYLACETIC ACID; DOPAMINE; GLIAL FIBRILLARY ACIDIC PROTEIN; HOMOVANILLIC ACID; TYROSINE 3 MONOOXYGENASE; ZONISAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DAMAGE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; MALE; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTICONVULSANTS; ANTIPARKINSON AGENTS; ASTROCYTES; CORPUS STRIATUM; DOPAMINE; GLIAL FIBRILLARY ACIDIC PROTEIN; HOMOVANILLIC ACID; ISOXAZOLES; MALE; MICE; MICE, INBRED C57BL; MPTP POISONING; NEURONS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

MUS; PARKINSONIA;

EID: 74149085603     PISSN: 08958696     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12031-009-9181-z     Document Type: Article

References (26)

1. Ahlskog, J. E., & Munenter, M. D. (2001). Frequency of levodoparelated dyskinesias and motor fluctuations as estimated from the cumulative literature. Movement Disorders, 16, 448-458. doi:10.1002/mds.1090.
2. Araki, T., Kumagai, T., Tanaka, K., et al. (2001). Neuroprotective effect of riluzole in MPTP-treated mice. Brain Research, 918, 176-181. doi:10.1016/S0006-8993 (01) 02944-4.
3. Asanuma, M., Miyazaki, I., Diaz-Corrales, F. J., et al. (2008). Preventing effects of a novel anti-parkinsonian agent zonisamide on dopamine quinone formation. Neuroscience Research, 60, 106-113. doi:10.1016/j.neures.2007.10.002.
4. Dauer, W., & Przedborski, S. (2003). Parkinson's disease: Mechanisms and models. Neuron, 39, 889-909. doi:10.1016/S0896-6273 (03) 00568-3.
5. +) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles. Biochemical and Biophysical Research Communications, 170, 1049-1055. doi:10.1016/0006-291X (90) 90498-C.
6. Hayakawa, T., Higuchi, Y., Nigami, H., & Hattori, H. (1994). Zonisamide reduces hypoxic-ischemic brain damage in neonatal rats irrespective of its anticonvulsive effect. European Journal of Pharmacology, 257, 131-136. doi:10.1016/0014-2999 (94) 90704-8.
7. Heikkila, R. E., Manzino, L., Cabbat, E. S., & Duvosion, R. C. (1984). Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydroxypyridine by monoamine oxidase inhibitors. Nature, 311, 467-469. doi:10.1038/311467a0.
8. Himeda, T., Mizuno, K., Kato, H., & Araki, T. (2005). Effects of age on immunohistochemical changes in the mouse hippocampus. Mechanisms of Ageing and Development, 126, 673-677. doi:10.1016/j.mad.2004.12.004.
9. Ito, T., Yamaguchi, T., Miyazaki, H., et al. (1982). Pharmacokinetic studies of AD-810, a new antiepileptic compound. Phase I trials. Arzneimittel-Forschung, 32, 1581-1586.
10. Komatsu, M., Hiramatsu, M., & Willmore, L. J. (2000). Zonisamide reduces the increase in a 8-hydroxy-2'-deoxyguanosine levels formed during iron-induced epileptogenesis in the brains of rats. Epilepsia, 41, 1091-1094. doi:10.1111/j.1528-1157.2000. tb00312.x.
11. 2 + antagonists on motor activity and the dopaminergic system I aged mice. Neurobiology of Aging, 24, 315-319. doi:10.1016/S0197-4580 (02) 00085-4.
12. Kurosaki, R., Muramatsu, Y., Kato, H., et al. (2005). Effect of angiotensin-converting enzyme inhibitor perindpril on iterneurons in MPTP-treated mice. European Neuropsychopharmacology, 15, 57-67. doi:10.1016/j.euroneuro.2004.05.007.
13. Mori, A., Noda, Y., & Packer, L. (1998). The anticonvulsant zonisamide scavenges free radicals. Epilepsy Research, 30, 153-158. doi:10.1016/S0920-1211 (97) 00097-1.
14. Muramatsu, Y., Kurosaki, R., Watanabe, H., et al. (2003). Cerebral alterations in a MPTP-mouse model of Parkinson's disease-an immunocytochemical study. Journal of Neural Transmission, 110, 1129-1144. doi:10.1007/s00702-003-0021-y.
15. Murata, M. (2004). Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease. Current Pharmaceutical Design, 10, 687-693. doi:10.2174/1381612043453180.
16. Murata, M., Hasegawa, K., & Kanazawa, I. (2007). Zonisamide improves motor function in Parkinson's disease. Neurology, 68, 45-50. doi:10.1212/01.wnl.0000250236.75053.16.
17. Ogawa, N., Asanuma, M., Miyazaki, I., Diaz-Corrales, F., & Miyoshi, K. (2005). L-DOPA treatment from the viewpoint of neuroprotection: Possible mechanism of specific and progressive dopaminergic neuronal death in Parkinson's disease. Journal of Neurology, 252 (Suppl. 4), iv23-iv31. doi:10.1007/s00415-005-4006-7.
18. Okada, M., Kaneko, S., Hirano, T., et al. (1995). Effects of zonisamide on dopaminergic system. Epilepsy Research, 22, 193-205. doi:10.1016/0920-1211 (95) 00078-X.
19. Rock, D., MacDonald, R., & Taylor, C. (1989). Blockade of sustained repetitive action potentials in cultured spinal cord neurons by zonisaimde (AD 810, CI 912), a novel anticonvulsant. Epilepsy Research, 3, 138-143. doi:10.1016/0920-1211 (89) 90041-7.
20. Schauf, C. (1987). Zonisamide enhances slow sodium inactivation in Myxicola. Brain Research, 413, 185-188. doi:10.1016/0006-8993 (87) 90168-5.
21. Sriram, K., Pai, K. S., Boyd, M. R., & Ravindranath, V. (1997). Evidence for generation of oxidative stress in brain by MPTP: In vitro and in vivo studies in mice. Brain Research, 749, 44-52. doi:10.1016/S0006-8993 (96) 01271-1.
22. Suzuki, S., Kawakami, K., Nishimura, S., et al. (1992). Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Research, 12, 21-27. doi:10.1016/0920-1211 (92) 90087-A.
23. Tanaka, A., Watanabe, Y., Kato, H., & Araki, T. (2007). Immunohistochemical changes to ageing in the mouse hippocampus and subventicular zone. Mechanisms of Ageing and Development, 128, 303-310. doi:10.1016/j.mad.2007.01.002.
24. Tipton, K. F., & Singer, T. P. (1993). Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. Journal of Neurochemistry, 61, 1191-1206. doi:10.1111/j.1471-4159.1993.tb13610.x.
25. Yokoyama, H., Takagi, S., Watanabe, Y., Kato, H., & Araki, T. (2008). Role of reactive nitrogen and reactive oxygen species against MPTP neurotoxicity in mice. Journal of Neural Transmission, 115, 831-842. doi:10.1007/s00702-008-0019-6.
26. Zigmond, M. J., & Stricker, E. M. (1989). Animals models of parkinsonism using selective neurotoxins: Clinical and basic implications. International Review of Neurobiology, 31, 1-9. doi:10.1016/S0074-7742 (08) 60277-9.